<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38382771</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2585</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of epidemiology</Title><ISOAbbreviation>Ann Epidemiol</ISOAbbreviation></Journal><ArticleTitle>The impact of COVID-19 vaccination prior to SARS-CoV-2 infection on prevalence of long COVID among a population-based probability sample of Michiganders, 2020-2022.</ArticleTitle><Pagination><StartPage>17</StartPage><EndPage>24</EndPage><MedlinePgn>17-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.annepidem.2024.02.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1047-2797(24)00031-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To estimate the association between COVID-19 vaccination status at the time of COVID-19 onset and long COVID prevalence.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used data from the Michigan COVID-19 Recovery Surveillance Study, a population-based probability sample of adults with COVID-19 (n&#xa0;=&#xa0;4695). We considered 30-day and 90-day long COVID (illness duration &#x2265;30 or &#x2265;90 days, respectively), using Poisson regression to estimate prevalence ratios (PRs) comparing vaccinated (completed an initial series &#x2265;14 days before COVID-19 onset) to unvaccinated individuals (received 0 doses before COVID-19 onset), accounting for differences in age, sex, race and ethnicity, education, employment, health insurance, and rurality/urbanicity. The full unvaccinated comparison group was further divided into historic and concurrent comparison groups based on timing of COVID-19 onset relative to vaccine availability. We used inverse probability of treatment weights to account for sociodemographic differences between groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to the full unvaccinated comparison group, the adjusted prevalence of 30-day and 90-day long COVID were lower among vaccinated individuals [PR<sub>30-day</sub>=&#xa0;0.57(95%CI:0.49,0.66); PR<sub>90-day</sub>=&#xa0;0.42(95%CI:0.34,0.53)]. Estimates were consistent across comparison groups (full, historic, and concurrent).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long COVID prevalence was 40-60% lower among adults vaccinated (vs. unvaccinated) prior to their COVID-19 onset. COVID-19 vaccination may be an important tool to reduce the burden of long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>MacCallum-Bridges</LastName><ForeName>Colleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Michigan Department of Epidemiology, 1415 Washington Heights, Ann Arbor, MI 48109, United States. Electronic address: maccallc@umich.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirschtick</LastName><ForeName>Jana L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>University of Michigan Department of Epidemiology, 1415 Washington Heights, Ann Arbor, MI 48109, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Akash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Michigan Department of Epidemiology, 1415 Washington Heights, Ann Arbor, MI 48109, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orellana</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>CDC Foundation., 600 Peachtree Street NE #1000, Atlanta, GA 30308, United States; Michigan Department of Health and Human Services, 333 South Grand Avenue, Lansing, MI 48933, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>University of Michigan Department of Biostatistics, 1415 Washington Heights, Ann Arbor, MI 48109, United States; University of Michigan Survey Research Center, 426 Thompson Street, Ann Arbor, MI 48104, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleischer</LastName><ForeName>Nancy L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>University of Michigan Department of Epidemiology, 1415 Washington Heights, Ann Arbor, MI 48109, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Epidemiol</MedlineTA><NlmUniqueID>9100013</NlmUniqueID><ISSNLinking>1047-2797</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012494" MajorTopicYN="N">Sampling Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular disease; EHR</Keyword><Keyword MajorTopicYN="N">Centers for Disease Control and Prevention; CI</Keyword><Keyword MajorTopicYN="N">Chronic obstructive pulmonary disease; COVID-19</Keyword><Keyword MajorTopicYN="N">Confidence interval; COPD</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019; CVD</Keyword><Keyword MajorTopicYN="N">Electronic health record; IPTW</Keyword><Keyword MajorTopicYN="N">Inverse probability of treatment weight; MDSS</Keyword><Keyword MajorTopicYN="N">Messenger ribonucleic acid; NH</Keyword><Keyword MajorTopicYN="N">Michigan COVID-19 Recovery Surveillance Study; mRNA</Keyword><Keyword MajorTopicYN="N">Michigan Disease Surveillance System; MI CReSS</Keyword><Keyword MajorTopicYN="N">Non-Hispanic; PCR</Keyword><Keyword MajorTopicYN="N">Polymerase chain reaction; PR</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 syndrome; COVID-19; COVID-19 vaccines; Population-based ABBREVIATIONS AND ACRONYMS: CDC</Keyword><Keyword MajorTopicYN="N">Prevalence ratio; US</Keyword><Keyword MajorTopicYN="N">United States; WHO World Health Organization.</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>22</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>21</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38382771</ArticleId><ArticleId IdType="doi">10.1016/j.annepidem.2024.02.007</ArticleId><ArticleId IdType="pii">S1047-2797(24)00031-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>